Cargando…
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6)...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360946/ https://www.ncbi.nlm.nih.gov/pubmed/35345374 http://dx.doi.org/10.31557/APJCP.2022.23.3.1005 |
_version_ | 1784764420843372544 |
---|---|
author | Watanabe, Mitsuru Katsumata, Kenji Sumi, Tetsuo Ishizaki, Tetsuo Enomoto, Masanobu Shigoka, Masatoshi Wada, Takahiro Kuwabara, Hiroshi Mazaki, Junichi Kasahara, Kenta Tago, Tomoya Udo, Ryutaro Nagakawa, Yuichi Kawachi, Shigeyuki Tsuchida, Akihiko |
author_facet | Watanabe, Mitsuru Katsumata, Kenji Sumi, Tetsuo Ishizaki, Tetsuo Enomoto, Masanobu Shigoka, Masatoshi Wada, Takahiro Kuwabara, Hiroshi Mazaki, Junichi Kasahara, Kenta Tago, Tomoya Udo, Ryutaro Nagakawa, Yuichi Kawachi, Shigeyuki Tsuchida, Akihiko |
author_sort | Watanabe, Mitsuru |
collection | PubMed |
description | BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6) and therapeutic efficacy was evaluated in patients with advanced/recurrent colorectal cancer (CRC). METHODS: Correlations between TS and DPD and primary and metastatic lesions in recurrent CRC were analyzed. Univariate and multivariate analyses of TS and DPD in combination with response rate (RR), progression-free survival (PFS), and overall survival (OS) were performed. RESULTS: A positive correlation between DPD and primary and metastatic lesions; correlations between TS and RR, DPD and RR, and PFS and OS; and significant differences for RR and DPD and TS, PFS and DPD, and OS and DPD were obtained. CONCLUSION: Nucleic acid metabolizing enzymes in primary lesions can be used to predict mFOLFOX6 efficacy in patients with recurrent CRC. |
format | Online Article Text |
id | pubmed-9360946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-93609462022-08-10 Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer Watanabe, Mitsuru Katsumata, Kenji Sumi, Tetsuo Ishizaki, Tetsuo Enomoto, Masanobu Shigoka, Masatoshi Wada, Takahiro Kuwabara, Hiroshi Mazaki, Junichi Kasahara, Kenta Tago, Tomoya Udo, Ryutaro Nagakawa, Yuichi Kawachi, Shigeyuki Tsuchida, Akihiko Asian Pac J Cancer Prev Research Article BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6) and therapeutic efficacy was evaluated in patients with advanced/recurrent colorectal cancer (CRC). METHODS: Correlations between TS and DPD and primary and metastatic lesions in recurrent CRC were analyzed. Univariate and multivariate analyses of TS and DPD in combination with response rate (RR), progression-free survival (PFS), and overall survival (OS) were performed. RESULTS: A positive correlation between DPD and primary and metastatic lesions; correlations between TS and RR, DPD and RR, and PFS and OS; and significant differences for RR and DPD and TS, PFS and DPD, and OS and DPD were obtained. CONCLUSION: Nucleic acid metabolizing enzymes in primary lesions can be used to predict mFOLFOX6 efficacy in patients with recurrent CRC. West Asia Organization for Cancer Prevention 2022-03 /pmc/articles/PMC9360946/ /pubmed/35345374 http://dx.doi.org/10.31557/APJCP.2022.23.3.1005 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Research Article Watanabe, Mitsuru Katsumata, Kenji Sumi, Tetsuo Ishizaki, Tetsuo Enomoto, Masanobu Shigoka, Masatoshi Wada, Takahiro Kuwabara, Hiroshi Mazaki, Junichi Kasahara, Kenta Tago, Tomoya Udo, Ryutaro Nagakawa, Yuichi Kawachi, Shigeyuki Tsuchida, Akihiko Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title_full | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title_fullStr | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title_full_unstemmed | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title_short | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer |
title_sort | nucleic acid metabolizing enzyme levels predict chemotherapy effects in advanced and recurrent colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360946/ https://www.ncbi.nlm.nih.gov/pubmed/35345374 http://dx.doi.org/10.31557/APJCP.2022.23.3.1005 |
work_keys_str_mv | AT watanabemitsuru nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT katsumatakenji nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT sumitetsuo nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT ishizakitetsuo nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT enomotomasanobu nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT shigokamasatoshi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT wadatakahiro nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT kuwabarahiroshi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT mazakijunichi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT kasaharakenta nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT tagotomoya nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT udoryutaro nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT nagakawayuichi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT kawachishigeyuki nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer AT tsuchidaakihiko nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer |